Type 2 Diabetes (T2D) is a disease that affects millions of people in the US and requires lifelong treatment.
As a result of the high prevalence of T2D-associated comorbidities, such as obesity and hypertension, key opinion leaders (KOLs) interviewed by GlobalData expressed the need for more T2D drugs that confer both glycemic and non-glycemic benefits. Recently FDA-approved T2D drugs that contain the aforementioned criteria include Novo Nordisk’s Ozempic (semaglutide) and Merck and Pfizer’s Steglatro (ertugliflozin), Segluromet (ertugliflozin + metformin), and Steglujan (ertugliflozin + sitagliptin). These novel treatments, which are all set to launch in the US in 2018, are expected to gain a significant share of the huge T2D market.
Ozempic is a once-weekly injectable T2D treatment that has been shown to provide significant reductions of both glycated haemoglobin (A1c) and the risk of major adverse cardiovascular (CV) events, as witnessed in the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6). Ozempic is a glucagon-like peptide-1 receptor agonist (GLP-1RA), a T2D injectable drug class that is increasingly prescribed to patients on oral anti-diabetic treatments who are struggling to get their blood glucose levels under control. On average, GLP-1RAs lower Hemoglobin A1c counts by approximately 1%–1.5%, and also provide the non-glycemic advantage of weight loss.
In clinical trials, treatment with Steglatro or its FDA-approved combination varieties, Segluromet and Steglujan, also resulted in significant A1c reductions. Steglatro belongs to the newest drug class on the T2D market, sodium-glucose co-transporter inhibitors (SGLT-2Is). The class harbours numerous non-glycemic advantages, such as weight loss and a reduction in systolic blood pressure. Although concerns regarding dehydration and amputation cases remain in patients taking SGLT-2Is, the drug class continues to be beneficial for T2D patients who are unable to adequately control their A1c levels.
With the T2D drug space becoming increasingly crowded, it is difficult to predict which agents will hold the majority of market share within drug classes over the next decade. Despite this, US KOLs believe that growth in the T2D treatment arena will be heavily driven by agents that confer both glycemic and non-glycemic benefits. In addition to lowering A1c, upcoming T2D drugs boast multiple non-glycemic attributes (such as CV benefits and weight and/or blood pressure reductions) that will help them stand out among the crowded T2D treatment space. As such, GlobalData expects Ozempic, Steglatro, Segluromet, and Steglujanto to gain substantial market share in the US over the next decade due to their superior clinical profiles and conferred non-glycemic benefits.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData